It is important to note that whilst there have been promising results treating RNF43 or RSPO2/3 mutant cancers with porcupine inhibitors, one on-target side effect of these drugs is a loss of bone density since WNT signalling plays an important role in bone homeostasis [65]. The gene discussed is RSPO2; the disease is cancer.